### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FO	RM	10	<b>-O</b>
			~

		rokwi 10-Q	
(Mark One) ☑	OF THE SECU	RT PURSUANT TO SECTIO URITIES EXCHANGE ACT ( rly period ended September 3	OF 1934
		or	
	OF THE SECU	RT PURSUANT TO SECTIO URITIES EXCHANGE ACT ( asition period from to _	OF 1934
	Commi	ssion File Number: 001-40578	3
	AGRIFORCE (	GROWING SYS' of registrant as specified in its c	TEMS LTD.
(State	ritish Columbia or other jurisdiction of oration or organization)		Not Applicable (I.R.S. Employer Identification No.)
Vano	2233 Columbia Street ouver, BC, Canada principal executive offices)		<b>V5Y 0M6</b> (Zip Code)
	(Registrant's to	(604) 757-0952 elephone number, including are	a code)
	(Former name or former addre	N/A ess and former fiscal year, if cha	anged since last report)
		red pursuant to Section 12(b)	
Title of each cla		ading Symbol(s)	Name of each exchange on which registered
Common Share Series A Warrar	~	AGRI AGRIW	NASDAQ Capital Market NASDAQ Capital Market
onths (or for such shorter period to dicate by check mark whether the	hat the registrant was required to file suc e registrant has submitted electronically a	h reports), and (2) has been sub and posted on its corporate Web	15(d) of the Securities Exchange Act of 1934 during the preceding 12 pject to such filing requirements for the past 90 days. Yes ⊠ No □ site, if any, every Interactive Data File required to be submitted and (or for such shorter period that the registrant was required to submit
dicate by check mark whether the	e registrant is a large accelerated filer, and "sm. dd filer," "non-accelerated filer" and "sm.		elerated filer, or a smaller reporting company. See the definitions of le 12b-2 of the Exchange Act.
Large accelerated	filer □		Accelerated filer □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.  $\Box$ 

Smaller reporting company ⊠ Emerging growth company  $\boxtimes$ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  $\square$  No  $\boxtimes$ 

Non-accelerated filer  $\boxtimes$ 

As of November 15, 2021, the registrant has 15,057,859 shares of common stock, no par value per share, outstanding.


#### TABLE OF CONTENTS

<u>PART I –</u>	<u> – FINANCIAL INFORMATION</u>	
Item 1.	Financial Statements	4
	Condensed Balance Sheets as of September 30, 2021 and December 31, 2020	4
	Condensed Statements of Operations for the three and nine months ended September 30, 2021 and September 30, 2020	5
	Condensed Statements of Shareholders' Equity for the three and nine months ended September 30, 2021 and September 30, 2020	6
	Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and September 30, 2020	7
	Notes to Condensed Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	16
Item 4.	Controls and Procedures	17
PART II -	— OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	18
Item 1A.	Risk Factors	18
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
Item 3.	Defaults Upon Senior Securities	18
Item 4.	Mine Safety Disclosures	18
Item 5.	Other Information	18
Item 6.	<u>Exhibits</u>	18

#### **Cautionary Note Regarding Forward-Looking Information**

This Quarterly Report on Form 10-Q contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements represent our expectations, beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding our assumptions about financial performance; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the defense industry, all of which were subject to various risks and uncertainties.

When used in this Quarterly Report on Form 10- Q and other reports, statements, and information we have filed with the Securities and Exchange Commission ("Commission" or "SEC"), in our press releases, in our periodic reports on Forms 10-K and 10-Q, in oral statements made by or with the approval of an executive officer, the words or phrases "believes," "may," "will," "expects," "should," "continue," "anticipates," "intends," "will likely result," "estimates," "projects" or similar expressions and variations thereof are intended to identify such forward-looking statements. However, any statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of important factors.

We do not assume the obligation to update any forward-looking statement. You should carefully evaluate such statements in light of factors described in this annual report. In this Quarterly Report on Form 10-Q, AgriFORCE Growing Systems Ltd. has identified important factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties.

#### PART I — FINANCIAL INFORMATION

#### Item 1. Financial Statements

#### AGRIFORCE GROWING SYSTEMS LTD.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (Unaudited) (Expressed in US dollars)

	Sep	tember 30, 2021	December 31, 2020		
ASSETS					
Current					
Cash and cash equivalents	\$	9,834,516	\$	653,410	
Other receivables		31,547		8,973	
Prepaid expenses and other current assets (Note 3)		479,870		213,038	
Total current assets		10,345,933		875,421	
Non-current					
Property and equipment, net		38,499		28,443	
Intangible asset (Note 4)		1,469,933		-	
Deferred IPO costs		-		390,932	
Construction in progress		2,069,630		2,071,093	
Total assets	\$	13,923,995	\$	3,365,889	
LIABILITIES AND EQUITY					
Current					
Accounts payable and accrued liabilities (Note 5)	\$	1,080,469	\$	1,930,988	
Contingent consideration payable		750,000		-	
Total current liabilities		1,830,469		1,930,988	
Non-current					
Warrants liability (Note 8)		1,842,895		-	
Long term loan (Note 7)		47,092		31,417	
Total liabilities		3,720,456		1,962,405	
Commitments and contingencies (Note 10)		- , - ,	•	, , , , ,	
Shareholders' equity					
Preferred Shares, no par value per share - unlimited shares authorized; nil and 2,258,826 shares					
issued and outstanding at September 30, 2021 and December 31, 2020, respectively*		-		6,717,873	
Common shares, no par value per share - unlimited shares authorized; 15,057,859 and 8,441,617					
shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively*		25,462,183		5,696,050	
Additional paid-in-capital		1,913,608		1,297,566	
Obligation to issue shares		102,345		94,885	
Accumulated deficit		(17,173,083)		(12,521,944)	
Accumulated other comprehensive income		(101,514)		119,054	
Total shareholders' equity		10,203,539		1,403,484	
Total liabilities and shareholders' equity	\$	13,923,995	\$	3,365,889	

<sup>\*</sup> reflects the 1:4.75 reverse stock split effected on November 29, 2020.

 $The \ accompanying \ notes \ are \ an \ integral \ part \ of \ these \ Condensed \ Consolidated \ Interim \ Financial \ Statements.$ 

#### AGRIFORCE GROWING SYSTEMS LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (Expressed in US dollars)

		Three Months Ended September 30,			Nine Months Ended September 30,			otember 30,
		2021		2020		2021		2020
OPERATING EXPENSES								
Consulting	\$	129,364	\$	54,415	\$	620,960	\$	362,760
Depreciation		2,283		2,285		7,606		6,697
Office and administrative		327,257		80,506		439,532		147,295
Investor and public relations		390,579		55,975		555,665		152,488
Professional fees		140,653		144,508		393,904		353,586
Rent		65,187		167		72,473		20,703
Research and development		116,857		921		178,117		114,352
Share-based compensation		415,597		217,291		571,398		463,882
Shareholder and regulatory		114,002		284,423		117,347		377,256
Travel and entertainment		28,545		46		39,851		5,723
Wages and salaries		650,456		140,419		989,421		580,309
Operating loss		(2,380,780)		(980,956)		(3,986,274)		(2,585,051)
OTHER EXPENSES								
Foreign exchange (gain) loss		(170,140)		(7,629)		(170,664)		2,011
Accretion of interest on senior secured debentures		57,019		(,,,=,)		484,379		_,,,,,
Change in fair value of warrants		(818,960)		_		(818,960)		-
Issuance cost related to warrants		375,123		_		375,123		_
Loss on extension of debt term		(204)		_		59,055		-
Boss on extension of deat term		(=+.)						
Loss before provision for income taxes		(1,823,618)		(973,327)		(3,915,207)		(2,587,062)
Provision for income taxes		_		_		_		_
Trovision for meonic taxes					_			
Net loss	\$	(1,823,618)	\$	(973,327)	\$	(3,915,207)	\$	(2,587,062)
Dividend paid to preferred shareholders	\$	203,674	\$	-	\$	735,932	\$	459,236
Net loss attributable to common shareholders	\$	(2,027,292)	\$	(973,327)	\$	(4,651,139)	\$	(3,046,298)
Other comprehensive income (loss)								
Foreign currency translation	\$	(228,317)	\$	34,612	\$	(220,568)	\$	(113,982)
Comprehensive loss attributable to common	•	(2.255.600)		(020 515)	Φ.	(4.051.505		(2.1 (2.20)
shareholders	\$	(2,255,609)	\$	(938,715)	\$	(4,871,707)	\$	(3,160,280)
Basic and diluted net loss attributed to common share*	\$	(0.14)	\$	(0.12)	\$	(0.46)	\$	(0.39)
		<u> </u>		<u> </u>		<u> </u>		
Weighted average number of common shares								
outstanding – basic and diluted*		14,378,354		7,936,767		10,144,800		7,821,064

<sup>\*</sup> reflects the 1:4.75 reverse stock split effected on November 29, 2020.

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

#### AGRIFORCE GROWING SYSTEMS LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (unaudited)

7,936,768

\$ 4,509,558

(Expressed in US dollars, except share numbers)

Balance, September 30, 2020

For the three and nine months ended September 30, 2021 and 2020

For the three months ended September 30 Series A Common Shares Preferred Share Accumulated Additional Obligation Total Other Paid-into Issue Accumulated Comprehensive Shareholders' # of Shares # of Shares Amount Amoun capital Shares Deficit Income Equity 270,020 Balance, July 1, 2021 \$ 7,022,883 \$ 6,717,873 \$ 1,453,367 \$ (15,145,791) 126,803 9.542.769 94.885 13,262,712 Shares issued for cash 3,127,998 13,262,712 Shares issued for Conversion of Series A preferred Stock 2,258,826 39,800 15,000 6,717,873 238,800 69,300 (2,258,826) (6717,873) Shares issued on exercise of warrants 44.644 283,444 Shares issues for consulting services 7,460 76,760 Share issued for settlement of accrued director's fee Shares issued for dividend on Preferred Shares 46,783 203,674 46,783 (203,674) 53,474 Share issue costs Share based compensation (2,099,842) 415,597 (2,099,842) 415,597 (1,823,618) (228,317) (1,823,618) Foreign currency translation (228.317) \$ (17,173,083) \$ 10,203,539 15,057,859 \$ 25,462,183 \$ 1,913,608 102,345 (101.514)Balance, September 30, 2021 1,791,369 106,521 217,291 Balance, July 1, 2020 7,936,768 \$ 4,509,558 2,258,826 \$ 6,717,873 972,947 \$ (10,425,325) 16,316 Shares issued for consulting services Share based compensation 106,521 217,291 (973,327) (973,327) Net loss 34,612 34,612 Foreign currency translation

2,258,826

\$ 6,717,873

\$ 1,190,238

106,521

\$ (11,398,652)

50,928

1,176,466

				For the nir	ne months ended	September 30			
	Commor	n Shares*	Serie Preferred						
	# of Shares	Amount	# of Shares	Amount	Additional Paid-in- capital	Obligation to Issue Shares	Accumulated Deficit	Accumulated Other Comprehensive Income	Total Shareholders' Equity
Balance, January 1, 2021	8,441,617	\$ 5,696,050	2,258,826	\$ 6,717,873	\$ 1,297,566	\$ 94,885	\$ (12,521,944)	\$ 119,054	\$ 1,403,484
Shares issued for cash	3,127,998	13,262,712	· · · ·	-	-	-		-	13,262,712
Shares issued for Conversion of series A preferred									
stock	2,258,826	6,717,873	(2,258,826)	(6,717,873)	-	-	-	-	-
Shares issued on exercise of warrants	39,800	238,800	-	-	44,644	-	-	-	283,444
Shares issued on cashless exercise of options	820,029	-	-	-	-	-	-	-	-
Shares issued for bonus	98,356	514,066	-	-	-	-	-	-	514,066
Shares issued for consulting services	62,237	349,809	-	-	-	7,460	-	-	357,269
Share issued for settlement of accrued director's									
fee	19,992	46,783	-	-	-	-	-		46,783
Shares issued for dividend on Preferred Shares	189,004	735,932	-	-	-	-	(735,932)	-	
Share issue costs	-	(2,099,842)	-	-		-	-	-	(2,099,842)
Share based compensation	-	-	-	-	571,398	-		-	571,398
Net loss	-	-	-	-	-	-	(3,915,207)	-	(3,915,207)
Foreign currency translation								(220,568)	(220,568)
Balance, September 30, 2021	15,057,859	\$ 25,462,183		\$ -	\$ 1,913,608	\$ 102,345	\$ (17,173,083)	\$ (101,514)	\$ 10,203,539
Balance, January 1, 2020	7,705,209	\$ 3,725,454	2,258,826	\$ 6,717,873	\$ 726,356	\$ 12,463	\$ (8,352,354)	\$ 164,910	\$ 2,994,702
Shares issued for consulting services	96,029	324,868	· · · -	-	-	94,058		-	418,926
Shares issued for dividend on Preferred Shares	135,530	459,236	-	-	-	-	(459,236)	-	-
Share based compensation	-	-	-	-	463,882	-	-	-	463,882
Net loss	-	-	-	-	-	-	(2,587,062)		(2,587,062)
Foreign currency translation							<u>-</u>	(113,982)	(113,982)
Balance, September 30, 2020	7,936,768	\$ 4,509,558	2,258,826	\$ 6,717,873	\$ 1,190,238	\$ 106,521	\$ (11,398,652)	\$ 50,928	\$ 1,176,466

<sup>\*</sup> reflects the 1:4.75 reverse stock split effected on November 29, 2020.

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

#### AGRIFORCE GROWING SYSTEMS LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Unaudited) (Expressed in US Dollars)

		For the nine months ended Septer			
		2021		2020	
CACH PLOWG PROMODED ATRICA ACTIVITIES					
CASH FLOWS FROM OPERATING ACTIVITIES  Net loss for the period	\$	(2.015.207)	\$	(2.597.062)	
Adjustments to reconcile net loss to net cash used in operating activities:	\$	(3,915,207)	Þ	(2,587,062)	
Depreciation		7,606		6,697	
Share-based compensation		571,398		463,882	
Shares issued for consulting services		298,214		418,926	
Loss on extension of debt term		59,055		410,920	
Issuance cost related to warrants		375,123		_	
Change in fair value of warrants		(818,960)		_	
Accretion of interest on senior secured debentures		484,379		_	
Changes in operating assets and liabilities:		707,577		_	
Other receivables		(22,574)		40,942	
Prepaid expenses and other current assets		(266,832)		(59,288)	
Accounts payable and accrued liabilities		210,330		82,129	
			_		
Net cash used in operating activities		(3,017,468)		(1,633,774)	
CASH FLOWS FROM INVESTING ACTIVITIES					
Acquisition of equipment		(17,866)		(851)	
Acquisition of intangibles		(225,000)		-	
Cash paid for construction in progress		(744,191)		-	
Net cash used in investing activities		(987,057)		(851)	
CASH FLOWS FROM FINANCING ACTIVITIES					
Proceeds from Initial Public Offering		15,639,990			
IPO costs paid including underwriting discount		(2,279,374)		(41,200)	
Proceeds from exercise warrants		238.800		(41,200)	
		15,932		29,987	
Proceeds from long-term loan Proceeds from issuance of senior secured debentures		600,000		29,967	
Financing costs of senior secured debentures				-	
		(69,000)		-	
Repayment of Senior Secured Debentures		(750,000)		<del>-</del>	
Net cash provided by financing activities		13,396,348		(11,213)	
		(210.717)		(50,522)	
Effect of exchange rate changes on cash and cash equivalent		(210,717)		(59,533)	
Change in cash		9,181,106		(1,705,371)	
Cash, beginning of period		653,410	_	2,158,891	
Cash, end of period	\$	9,834,516	\$	453,520	
Supplemental cash flow information:					
Cash paid during the period for interest	\$	_	\$	_	
Cash paid during the period for income taxes	\$	-	\$	-	
Supplemental disclosure of non-cash investing and financing transactions					
Fair Value of warrants liability	\$	374,028	\$		
Preferred stock dividend paid in common shares	\$ \$	735,932	\$	459.236	
Unpaid amount related to construction in progress included in accounts payable	\$ \$	135,932	\$	744,191	
Conversion of Series A preferred stock to common shares	\$ \$	6,717,873	Ф	/44,191	
Unpaid IPO costs	\$ \$	0,/1/,8/3	\$	84,569	
Unpaid amount related to intangible assets included in accrued expenses	\$ \$	500,000	\$	04,309	
Onpara amount related to intangible assets included in accrued expenses	Ą	300,000	Φ		

The accompanying notes are an integral part of these Condensed Consolidated Interim Financial Statements.

#### NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the nine months ended September 30, 2021 and 2020 (unaudited) (Expressed in US Dollars, except where noted)

#### 1. NATURE OF OPERATIONS AND BASIS OF PREPARATION

#### **Business Overview**

AgriFORCE Growing Systems Ltd. (the "Company") is an innovative agriculture-focused technology company that delivers reliable, financially robust solutions for high value crops through our proprietary facility design and automation Intellectual Property to businesses and enterprises globally. The Company intends to operate in the plant based pharmaceutical, and other high value crop markets using its unique proprietary facility design and hydroponics based automated growing system that enable cultivators to effectively grow crops in a controlled environment. The Company calls its facility design and automated growing system the "AgriFORCE grow house." The Company has designed its AgriFORCE grow house to produce in virtually any environmental condition and to optimize crop yields to as near their full genetic potential possible whilst substantially eliminating the need for the use of pesticides and/or irradiation

#### **Basis of Presentation**

The accompanying Condensed Consolidated Interim Financial Statements (the "interim financial statements") and related financial information of AgriFORCE Growing Systems Ltd. (the "Company") should be read in conjunction with the audited financial statements and the related notes thereto for the years ended December 31, 2020 and 2019 included in the Company's Registration Statement on Form S-1/A (File No. 333-251380), which was filed with the Securities Exchange Commission ("SEC") on June 30, 2021. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the United States Securities and SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by the accounting principles generally accepted in the United States of America ("U.S. GAAP") for complete financial statements.

The accompanying interim financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020, and the related interim information contained within the notes to the interim financial statements, are unaudited. The interim financial statements have been prepared in accordance with U.S. GAAP and on the same basis as the audited financial statements. In the opinion of management, the accompanying interim condensed financial statements contain all adjustments which are necessary to state fairly the Company's financial position as of September 30, 2021, and the results of its operations and cash flows for the nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2021, or for any future period.

#### Liquidity and Management's Plan

In accordance with Accounting Standards Update No. 2014-15, *Presentation of Financial Statements – Going Concern (Subtopic 205-40)*, the Company's management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.

As of September 30, 2021, the Company had cash and cash equivalent of \$9,834,516. During the three and nine months ended September 30, 2021, the Company incurred a net loss of \$1,823,618 and \$3,915,207, respectively, and used \$3,017,468 of cash in operating activities during the nine months ended September 30, 2021. At September 30, 2021, the Company had an accumulated deficit of \$17,173,083 and currently does not expect to experience positive cash flows from operating activities in the near future as it continues expanding the organization to support planned growth while also continuing to invest in research and development and other commercialization efforts of its technology that is currently in development. We also expect to incur significant additional expenditures as a public company.

Although it is difficult to predict the Company's liquidity requirements, as of September 30, 2021, and based upon the Company's current operating plan and the net proceeds received from its July 2021 initial public offering ("IPO") (see Note 9), the Company believes that it will have sufficient cash to meet its projected operating requirements for at least the next 12 months following the issuance of the interim financial statements based on the balance of cash.

#### 2. SIGNIFICANT ACCOUNTING POLICIES

#### Recent Accounting Pronouncements

Effective January 1, 2021, the Company adopted ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred tax liabilities, the incremental approach for intra-period tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax), which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The adoption of this new guidance did not have a material impact to these interim financial statements.

In August 2020, the FASB issued ASU 2020-06 "Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity's Own Equity" ("ASU 2020-06"). The intention of ASU 2020-06 is to address the complexities in accounting for certain financial instruments with a debt and equity component. Under ASU 2020-06, the number of accounting models for convertible notes will be reduced and entities that issue convertible debt will be required to use the if-converted method for the computation of diluted "Earnings per share" under ASC 260. ASC 2020-06 is effective for fiscal years beginning after December 15, 2021 and may be adopted through either a modified retrospective method of transition or a fully retrospective method of transition. The Company is currently assessing the impact this guidance will have on our condensed consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04 - Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). ASU 2021-04 clarifies and reduces diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. Modifications and exchanges should be treated as an exchange of the original instrument for a new instrument. The amendment requires entities to measure the effect as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged if the modification or the exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements.

For all other modifications or exchanges, the effect should be measured as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged for all other modifications or exchanges. The amendments require entities to recognize the effect on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The amendments also require entities to recognize the effect in accordance with the guidance in Topic 718, Compensation - Stock Compensation. ASU No. 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. ASU 2021-04 will be adopted on January 1, 2022. The Company is currently assessing the impact this guidance will have on our condensed consolidated financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

#### Loss per Common Share

The Company presents basic and diluted loss per share data for its common shares. Basic loss per common share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potentially dilutive share equivalents, such as stock options and warrants and assumes the receipt of proceeds upon exercise of the dilutive securities to determine the number of shares assumed to be purchased at the average market price during the year. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the three and nine months ended September 30, 2021 and September 30, 2020, since the effect of the Company's stock options and warrants are anti-dilutive.

#### Fair Value of Financial Instruments

The fair value of the Company's accounts receivable, accounts payable and other current liabilities approximate their carrying amounts due to the relative short maturities of these items.

As part of the issuance of debentures on March 24, 2021, the Company issued warrants having strike price denominated in U.S. Dollars. This creates an obligation to issue shares for a price that is not denominated in the Company's functional currency and renders the warrants not indexed to the Company's stock, and therefore, must be classified as a derivative liability and measured at fair value. On the same basis, the Series A Warrants and the representative warrants issued as part of the IPO are also classified as a derivative liability and measured at fair value.

The fair value of the Company's warrants is determined in accordance with FASB ASC 820, "Fair Value Measurement," which establishes a fair value hierarchy that prioritizes the assumptions (inputs) to valuation techniques used to price assets or liabilities that are measured at fair value. The hierarchy, as defined below, gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The guidance for fair value measurements requires that assets and liabilities measured at fair value be classified and disclosed in one of the following categories:

- Level 1: Defined as observable inputs, such as quoted (unadjusted) prices in active markets for identical assets or liabilities.
- Level 2: Defined as observable inputs other than quoted prices included in Level 1. This includes quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3: Defined as unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

As of September 30, 2021, the Company's warrant liability related to IPO warrants and representative's warrant amounting to \$1,771,481 (December 31, 2020 - \$nil) is reported at fair value and categorized as Level 1 inputs, whereas fair value of warrant liability related to Bridge warrants amounting to \$71,414 (December 31, 2020 - \$nil) is categorized as level 3 inputs. (see Note 6 and Note 8).

The Company has reclassified certain amounts in the 2020 consolidated financial statements to comply with the 2021 presentation.

#### 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS

	Septe	September 30, 2021		December 31, 2020
Deposits	\$	170,000	\$	170,000
Legal retainer		70,295		43,038
Prepaid insurance		139,473		-
Others – office lease deposit		100,102		-
	\$	479,870	\$	213,038

During the year ended December 31, 2020, the Company entered into a land purchase agreement in relation to construction of a facility in Coachella, California. A deposit of \$170,000 has been paid and the balance of the purchase price is subject to financing. On April 6, 2021, the scheduled close of escrow was extended to April 30, 2021 and the purchase price was increased to \$4.4 million. The Company is currently renegotiating the final terms of the debt financing related to the purchase of land before completing the purchase.

#### 4. INTANGIBLE ASSET

Intangible asset represents Intellectual Property ("IP") acquired under an Asset purchase agreement from Manna Nutritional Group, LLC ("MNG") on September 10, 2021. The IP encompasses patent-pending technologies to naturally process and convert grain, pulses and root vegetables, resulting in low-starch, low-sugar, high-protein, fiber-rich baking flour products, as well as a wide range of breakfast cereals, juices, natural sweeteners and baking enhancers. The terms of the agreement are as below:

The aggregate purchase price for the Purchased Assets (the "Purchase Price") is up to \$14,475,000, and shall consist of the following, subject to the terms and conditions of this Agreement, as follows:

- (i) The number of shares of Company's common stock (rounded up to the nearest whole number), restricted as to resale under Section 4(a)(2) of the Securities Act, equal to the quotient of (i) \$5,000,000 divided by (ii) a per share price equal to the average of the volume weighted average price ("VWAP") of the Company's common shares for the ten trading days immediately preceding the Due Diligence Deadline (as defined below) (the "Closing Shares"). The Closing Shares, to be due on the Closing Date, which Closing Shares are restricted as to resale and issued under a private placement exempt from registration under Section 4(a) (2) of the Securities Act, are subject to release of restriction and lockup on a quarterly basis over ten quarters commencing on the Closing Date in equal amounts of shares over ten consecutive calendar quarters. The Closing Shares are due and will be issued to MNG upon the date that is 180 days from the Effective Date (September 10, 2021) (the "Due Diligence Deadline"), with such due diligence being comprised of (the following three bullet points are the key performance indicators "KPIs"):
  - Receipt and Tasting of Flours and Sweeteners by the Company;
  - Independent Lab Testing of Flours and Sweeteners by the Company to confirm fiber, protein, and starch content of such products meets the specifications provided by MNG; and
  - Completion by the Company of Third-Party Engineering Process Analysis, included in the scope of work outlined by Covert Engineers, dated August 11, 2021, for conceptual and preliminary plant design for a Pilot Manufacturing Facility.
- (ii) \$1,475,000 in cash, minus any amounts paid to MNG under (iii), payable to MNG at Closing;
- (iii) \$725,000 in cash payable follows: (a) \$225,000 payable on the Effective Date; and (b) \$500,000 payable within 120 days after the Effective Date, to reimburse MNG for, without limitation, satisfaction of all the secured debt as listed in Section 2.04 of the Disclosure Schedules to the Agreement (the "Secured Debt").
- (iv) The number of shares of Company's common stock (rounded up to the nearest whole number) to be issued in two tranches that equals (i) \$8,000,000 divided by (ii) a per share price equal to the VWAP of the Company's common shares for the ten trading days immediately before the issuance date of those shares ("Post Closing Shares"). \$5,000,000 of the Post-Closing Shares will be issued on June 30, 2022, to be held in Escrow. \$3,000,000 of the Post-Closing Shares will be issued to MNG on December 31, 2022, to be held in Escrow. All distributions and dividends attributable to the Post-Closing Shares (collectively, "Dividends") will accrue for the benefit of MNG and will be held in Escrow pending release of the Post-Closing Shares, in which case all Dividends will be released to MNG at the same time as the Post-Closing Shares are so released. Until Post-Closing Shares are released from Escrow, all voting rights thereto shall be exercised as directed by the Company's Board of Directors. If a Patent is issued within 24 months of the Closing Date, and such Patent is transferred to the Company free and clear of all encumbrances, then the Post-Closing Shares shall be released from Escrow in four equal amounts commencing on the date of issuance of the Patent and then for the three subsequent three-month anniversaries thereof.

In the event that after 24 months from the closing date, a Patent does not issue from the IP, Buyer's obligation to issue the Post-Closing Shares and Dividends to MNG will be deemed null and void ab initio and will no longer be due and owing to MNG, and the Post-Closing Shares shall be released from escrow and returned to the Company, and the Purchase Price shall be adjusted downward dollar for dollar.

Based on the terms above and in conformity with US GAAP, the Company accounted for purchase as an asset acquisition and has deemed the asset purchased as an in-process research and development. The Company has further deemed the asset to be of indefinite life until the completion of the associated research and development ("R&D") activities. Once completed and commercialized, the asset will be amortized over its useful life. The recognition of the IP asset is based on the payments made to date of \$225,000 and contingent consideration that is probable and reasonably estimable as of the reporting date. Subsequent changes in contingent consideration are recorded against cost. As of September 30, 2021, the company has recorded \$500,000 under accrued expenses, related to reimbursement for satisfaction of secured debt of seller. Further, the company has recorded \$750,000 as contingent consideration, which is considered probable and due on closing. The remaining amounts payable as described above were not deemed to be probable at September 30, 2021, and accordingly have not been accrued for.

#### 5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	Septem	September 30, 2021		December 31, 2020
Accounts payable	\$	197,187	\$	991,565
Accrued expenses		813,861		905,629
Others		69,421		33,794
Accounts Payable and Accrued Liabilities	\$	1,080,469	\$	1,930,988

Accounts payable includes \$nil (December 31, 2020 - \$744,191) payable to an outside contractor in relation to facility construction. Accrued expenses include bonus payable of \$nil (December 31, 2020 - \$487,983), settlement of secured debt related to IP asset of \$500,000 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$29,817 (December 31, 2020 - \$nil) and Directors' fees payable of \$

31, 2020 - \$128,448). Accounts payable and accrued liabilities include a total unpaid IPO cost of \$nil (December 31, 2020 - \$297,437).

#### 6. SENIOR SECURED DEBENTURES

On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of \$750,000 in principal amount (\$600,000 subscription amount) of senior secured debentures originally due June 24, 2021 (the "Bridge Loan"). The imputed interest rate is encompassed within the original issue discount of the debentures and no additional cash interest shall be due. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended. Transaction costs of \$69,000 have been recorded in connection with the Bridge Loan.

On June 24, 2021, the due date was extended, for which the Company paid an extension fee of 10,000 common shares with a fair value of \$60,000. The senior secured debentures were repaid in full on July 13, 2021.

As part of the bridge loan, the debenture holder was issued warrants (the "Bridge Warrants") to purchase 93,938 common shares with a strike price of \$3.99 per share. The term of the warrants is three years. In accordance with U.S. GAAP, the fair value of the warrants was recorded as a liability in the accompanying balance sheet at September 30, 2021 using Black-Scholes option-pricing model. The Company remeasures the fair value of the warrants liability at each reporting date until the warrants are exercised or have expired. Changes in the fair value of the warrants liability is reported in the statements of comprehensive income / (loss) as income or expense. The fair value of the warrants liability is subject to significant fluctuation based on changes in the inputs to the Black-Scholes option-pricing model, including our common stock price, expected volatility, expected term, the risk-free interest rate and dividend yield. The market price for our common stock may be volatile. Consequently, future fluctuations in the price of our common stock may cause significant increases or decreases in the fair value of the warrants.

The changes in the fair value of the Bridge Warrants amounting to \$199,255 is charged to the statement of comprehensive income / (loss). The fair value of the warrants estimated at \$71,414 determined using the Black-Scholes option pricing model was based on the following assumptions; stock price \$2.23, dividend yield – nil, expected volatility 75%, risk free rate of return 0.67%, expected term of 3 years.

#### 7. LONG TERM LOAN

During the year ended December 31, 2020, the Company entered into a loan agreement with Alterna Bank for a principal amount of \$31,417 (CAD\$ 40,000) under Canada Emergency Business Account Program (the "Program").

The Program, as set out by the Government of Canada, requires that the funds from this loan shall only be used by the Company to pay non-deferrable operating expenses including, without limitation, payroll, rent, utilities, insurance, property tax and regularly scheduled debt service, and may not be used to fund any payments or expenses such as prepayment/refinancing of existing indebtedness, payments of dividends, distributions and increases in management compensation.

The loan is interest free for an initial term that ends on December 31, 2022. Repaying the loan balance on or before December 31, 2022 will result in loan forgiveness of 25% (up to CAD \$10,000). Any outstanding loan after initial term carries an interest rate of 5% per annum, payable monthly during the extended term i.e. January 31, 2023 to December 31, 2025.

In April 2021, the Company applied for additional loan with Alterna Bank under the Program and received \$15,932 (CAD\$20,000). The expansion loan is subject to the original terms and conditions of the Program.

#### 8. WARRANT LIABILITY

As of September 30, 2021, the warrant liability represents aggregate fair value of publicly traded 3,088,198 Series A Warrants, 135,999 representative's warrants, and 93,938 Bridge warrants.

The representative's warrant is exercisable one year from the effective date of the registration statement for the IPO and will expire three years after the effective date. The exercise price of the representative's warrant is \$6 per share. The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA. The underwriter (or permitted assignees under Rule 5110(e)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from the date of this prospectus. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation.

The change in fair value on the warrant liability amounting to \$818,960 is recorded in the statement of comprehensive loss for the nine months ended September 30, 2021.

#### 9. SHARE CAPITAL

On March 29, 2021, the Company issued 30,000 common shares with a fair value of \$179,700 against consulting services from a third party.

On May 10, 2021, the Company declared, and on May 11, 2021 issued, 86,739 common shares as stock dividend to holders of Series A Preferred shares issued on May 2, 2019.

On May 10, 2021, the Company declared, and on May 11, 2021 issued, 48,791 common shares as stock dividend to holders of Series A Preferred shares issued on May 10, 2019.

On May 27, 2021, the Company issued to consultants a total of 7,237 common shares.

On May 27, 2021, the Company issued 820,029 common shares as a result of 1,113,701 stock options exercised on a cashless basis at various exercise prices.

On May 28, 2021, the Company's officers opted to receive a total of 98,356 common shares as bonus compensation for services rendered and accrued for in 2019 and 2020.

On May 31, 2021, the Company granted a total of 405,059 stock options to directors, officers, employees, and consultants of the Company. The stock options will vest over the next three years following the grant date with the first vesting date of three-month anniversary after the grant date. The stock options are exercisable for a five-year period at an exercise price of \$7.00. The fair value of the options was estimated at \$1.48 million determined using the Black-Scholes option pricing model was based on the following assumptions; stock price \$6.00, dividend yield – nil, expected volatility 80%, risk free rate of return 0.98%, expected term of 3 years.

On July 15, 2021 the Company granted a total of 55,445 stock options to an officer of the Company. The stock options will vest over the next three years following the grant date with the first vesting date of three-month anniversary after the grant date. The stock options are exercisable for a five-year period at an exercise price of \$7.00. The fair value of the options was estimated at \$85,693 determined using the Black-Scholes option pricing model was based on the following assumptions; stock price \$3.86, dividend yield – nil, expected volatility 80%, risk free rate of return 0.88%, expected life of 3 years.

On September 30, 2021 the Company granted a total of 49,284 stock options to directors of the Company. The stock options will vest over the next three years following the grant date with the first vesting date of three-month anniversary after the grant date. The stock options are exercisable for a five-year period at an exercise price of \$7.00. The fair value of the options was estimated at \$32,530 determined using the Black-Scholes option pricing model was based on the following assumptions; stock price \$2.30, dividend yield – nil, expected volatility 80%, risk free rate of return 1.11%, expected life of 3 years.

As of September 30, 2021, there was \$901,575 of total unrecognized compensation cost related to unvested share-based compensation granted under the stock option plan; that cost is expected to be recognized over a period of 3 years.

On June 24, 2021, the Company issued to a consultant working with the senior secured debentures holders, a total of 10,000 common shares on their behalf, for the term extension of the Bride Loan (see Note 6).

On July 12, 2021, the Company completed its IPO whereby it sold a total of 3,127,998 units, each consisting of one common share and one Series A warrant to purchase one common share, at a public offering price of \$5.00 for gross proceeds of \$15,639,990. The Company received net proceeds from the IPO of \$14,388,791, after deducting underwriting discounts and commissions of 1,251,199.

Concurrent with the closing of the IPO, the 2,258,826 common shares were issued upon the conversion of all of its issued and outstanding Series A Preferred Shares.

On July 13, 2021, the Company declared and issued, 53,474 common shares as final stock dividend to the holders of Series A Preferred shares.

On July 13, 2021, the Company issued to consultants a total of 15,000 common shares.

On July 15, 2021, the Company issued 39,800 common shares as a result of exercise of 39,800 Series A warrants on cash basis at an exercise price of \$6 per warrant.

On July 28, 2021, 93,938 common stock purchase warrants were issued to the purchaser of the senior secured debentures, with a term of three years and a strike price per share of \$3.99.

On Sep 01, 2021, the Company issued to Directors 19,992 common shares as settlement of accrued directors' fee.

#### 10. COMMITMENTS AND CONTINGENCIES

#### Lease commitments

The Company entered into an operating lease for office space. The minimum future payments under the lease for our continuing operations in each of the years ending December 31 is as

Remainder of 2021	\$ 68,137
2022	\$ 273,962
2023	\$ 279,610
2024	\$ 289,495
2025	\$ 306,442
2026	\$ 306,442
Subsequent years	\$ 842,714
	\$ 2,366,802

#### Litigation

During the nine months ended September 30, 2021 and the year ended December 31, 2020, the Company had no new contingencies to disclose.

During the year ended December 31, 2018, the Company entered into a purchase agreement with certain parties representing proprietary technology. As consideration for the purchase of the technology and attendant intellectual property rights, the Company issued an aggregate of 5,263,158 (25,000,000 before the Reverse Split) Class A common voting shares (the "Class A Shares").

An additional 105,263 (500,000 before the Reverse Split) Class A Shares were issued for consulting services to assist with application of the proprietary technology to the Company's business.

Subsequent to the execution of these agreements, the Company was notified as to certain issues relating to the transaction agreements that were executed and the intellectual property risks that were purportedly transferred. After several months of analysis with various professionals, the Company determined that the technology was in fact invalid and therefore without any value.

On May 15, 2019, a claim by HydroHaus Horticulture, Inc., Stuart Brazier and Christopher Gielnik was filed in BC Supreme Court. The basic allegations against Agriforce Growing Systems Ltd. are:

- 1. The Company breached the manufacturing agreement under which HydroHaus Horticulture claims it had the exclusive right to build hydro houses for the Company;
- 2. The Company advised HydroHaus Horticulture that it was in breach of the licensing agreement relating to its project to build a hydro house for the Nak'azdli causing HydroHaus Horticulture to spend approximately \$130,000 to change the way it was to perform that contract;
- 3. The Company owes approximately \$100,000 for expenses paid for by HydroHaus Horticulture, which has not been accrued for at this time as management does not believe the merits are valid. Should any amounts be required to be paid as a result of the claim, the Company will appropriately record at that time; and
- 4. The Company wrongfully rescinded its agreements with HydroHaus Horticulture.

The plaintiffs are seeking general and special damages, alternatively rescission of the agreements or specific performance of those agreements and payment for expenses incurred by HydroHaus Horticulture for the benefit of the Company. The plaintiffs are also seeking an order that the Hydrohaus IP (allegedly comprising certain cladding materials and methods of insulating greenhouses, regulating humidity, moving growing plants, and managing the movement of air, and any derivative works), and an associated patent application, be transferred to them. The Plaintiffs are also seeking an order prohibiting the Company from using the words, "Canivate", "the Canivate Way", "HydroFilm", "Hydrohouse" and "Hydrohaus".

On May 24, 2019, the Company filed a Response to the claim. That response denies the allegations in the claim, raises the defense that the plaintiffs wrongfully purported to sell intellectual property which they falsely stated they had invented and owned and states that the intellectual property was unworkable to build greenhouses. The Company also alleges that the plaintiffs falsely represented that their work for the Kak'adzdli would benefit the Company when it would not. The Response asks that the claim be dismissed.

The Company has also filed a Counterclaim based upon its allegations that the plaintiffs wrongfully induced the Company to enter agreements with the plaintiffs based on fraudulent misrepresentations regarding the existence of ownership of intellectual property. Further, the counterclaim alleges that Mr. Brazier breached his fiduciary duties to Canivate in preferring the interests of Hydrohaus over those of the Company.

The counterclaim seeks a declaration that the agreements which the Company rescinded were properly rescinded based upon the misrepresentations of the plaintiffs as well as general, special, aggravated and punitive damages, an accounting for profits, and legal costs.

During the nine months ended September 30, 2021 and the year ended December 31, 2020, there has been no further activity in the lawsuit. Based on Company's litigation counsel's opinion, management does not believe the potential monetary damages to be material based on the damages sought by the plaintiff.

#### 11. SUBSEQUENT EVENTS

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were issued and has determined that no material subsequent events exist, except for events previously disclosed in the notes to the financial statements, and the negotiation of the terms of debt financing related to purchase of land as disclosed in Note 3.

#### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

#### **Company History and Our Business**

AgriFORCE Growing Systems Ltd. was incorporated as a private company by Articles of Incorporation issued pursuant to the provisions of the British Columbia Business Corporations Act on December 22, 2017. The Company's registered and records office address is at 300 – 2233 Columbia Street, Vancouver, British Columbia, Canada, V5Y 0M6. On February 13, 2018, the Company changed its name from 1146470 B.C. Ltd to Canivate Growing Systems Ltd. On November 22, 2019, the Company changed its name from Canivate Growing Systems Ltd. to AgriForce Growing Systems Ltd.

The Company is an innovative agriculture-focused technology company that delivers reliable, financially robust solutions for high value crops through our proprietary facility design and automation intellectual property to businesses and enterprises globally. The Company intends to operate in the plant based pharmaceutical, nutraceutical, and other high value crop markets using its unique proprietary facility design and hydroponics based automated growing system that enable cultivators to effectively grow crops in a controlled environment. The Company calls its facility design and automated growing system the "AgriFORCE grow house". The Company has designed its AgriFORCE grow house to produce in virtually any environmental condition and to optimize crop yields to as near their full genetic potential as possible whilst substantially eliminating the need for the use of pesticides and/or irradiation.

#### Our Business Plan

The Company plans to develop its business by focusing on both an organic growth plan and through mergers and acquisitions. The Company's organic growth plan is focused on four distinct phases:

#### PHASE 1: COMPLETED: 2017-2020

- Conceptualization, Engineering, and Design of Facility and Systems.
- Completed selection process of key environmental systems with preferred vendors.
- The signing of revenue contracts with the Exclusive Independent Operator (EIO) for the first three facilities completed.
- The arrangement of three offtake agreements signed with Exclusive Independent Operator (EIO) for those three facilities when complete .(Subsequently these agreements were terminated in Q2 2021)
- Selection and Land Purchase agreement in Coachella, CA for 41.37-acre parcel subject to financing completion in 2021.
- · ForceFilm material ordered.

#### PHASE 2: 2021:

- Complete the financing for and purchase of the 41.37-acre land parcel in Coachella, CA
- Complete new contracts' structures for those first three facilities with new independent operators.
- Site preparation and utilities infrastructure build out for the campus (up to eight facilities).
- Fit out and complete genetics lab for micropropagation, breeding, and R&D to achieve near term revenue (8 months) of the sale of tissue culture clones for variant crops.
- Additional raw materials procurement of AgriFORCE IP specific automated grow system, supplemental grow lighting and controls systems, and manufacture of the building envelope materials.
- Conceptualization and design of vertical grow solutions in order to develop a small-scale vertical grow house.
- Focus on the delivery and installation of the first facility.
- Initiate the design of a R&D facility for food solutions and plant-based pharma.

#### PHASE 3: 2022-2024:

- Focus on the delivery and installation of the second and third facilities. Proof of quantitative and qualitative benefits will drive both sales pipeline acceleration for subsequent years.
- Complete the design and construction of a R&D facility for food solutions and plant-based pharma. Commence engagement with universities and pharmaceutical companies.
- Construct small scale vertical grow house and operate successfully.
- Finalize the design and engineering of vertical grow solution with construction commencement late in the third year. Commence engagement with local restaurants and grocery stores and develop a vertical grow house branding strategy.

#### PHASE 4: 2025:

- Focus on delivery and installation of additional facilities.
- Expand geographic presence into other states whilst also introducing the grow house to other international markets with a view to securing additional locations and markets by year four.
- Targeted additional contracts of three facilities.
- Commence and complete first vertical grow commercial facility to serve Southern California market by end of year 4.

The Company's initial AgriFORCE grow houses are planned to be constructed in California.

With respect to M&A growth, the Company is creating a separate corporate office to aggressively pursue acquisitions. The Company will focus on identifying target companies in the key four pillars of its platform where each separate element of the business has its existing legacy business *and* can leverage across areas of expertise to expand their business footprint. The Company believes that a buy and build strategy will provide unique opportunities for innovation across each segment of the Ag-Tech market we serve. Our unique IP combined with the know-how and IP of acquired companies will create additional value if the way we grow or produce crops. The Company believes there is currently no other public traded publicly in the United States pursing this model.

#### COVID-19

Management has evaluated the impact of the COVID-19 pandemic on the industry and has concluded that it has not impacted the Company's business operations or ability to raise the capital necessary to continue its operations.

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for private companies.

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an "emerging growth company," we intend to rely on certain of these exemptions from, without limitation, (i) providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an "emerging growth company" until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in which our annual gross revenues exceed \$1.07 billion, (c) the last day of our fiscal year in which we are deemed to be a "large accelerated filer" as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds \$700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date on which we have issued more than \$1 billion in nonconvertible debt during the preceding three-year period.

#### FOR THE THREE MONTHS AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020

#### **Results of Operations**

The following discussion should be read in conjunction with the condensed unaudited financial statements for the interim periods ended September 30, 2021 and 2020 respectively, included in this report.

#### Revenues

The Company has generated no revenue since inception.

#### **Operating Expenses**

Operating expenses increased in the three months ended September 30, 2021 as compared to September 30, 2020 by \$1,399,824 or 143%, primarily due to increase in wages and salaries by \$510,037, increase in investor relations by \$334,604 and increase in office and administrative expense of \$246,751, as the Company entered into growth phase post IPO and increased its staff and operations. This was partially offset by declines in shareholder and regulatory expenses of \$170,421.

Overall, operating expenses for the nine months ended September 30, 2021 increased by \$1,401,223 or 54% as compared to September 30, 2020. Wages and salaries increased by \$409,112, investor relations expense increased by \$403,177, office and administrative expenses increased by \$292,237, and consulting expense increased by \$258,200 due to increased costs associated with implementing post IPO growth plans and operating as a publicly traded company. The increase in operating expenses is partially offset by the decrease in shareholder and regulatory expense by \$259,909.

#### Other (Income) / Expenses

Other expenses for the three months and nine months ended September 30, 2021 mainly relate to accretion of interest and loss on extension of the term related to the senior secured debentures issued by the Company on March 24, 2021, and issue costs of public offer related to Series A Warrants. Other expenses were offset by change in fair value of warrant liability amounting to \$818,960 and foreign exchange gains of \$170,140.

#### **Net Loss**

The Company recorded a net loss of \$1,823,618 for the three months ended September 30, 2021 as compared to a net loss of \$973,327 for the three months ended September 30, 2020. The increase in net loss is due to the total increase in operating expenses and other expenses outlined above.

The Company recorded a net loss of \$3,915,207 for the nine months ended September 30, 2021 as compared to a net loss of \$2,587,062 for the nine months ended September 30, 2020. The increase in net loss is due to the total increase in operating expenses and other expenses outlined above.

#### **Liquidity and Capital Resources**

The Company's primary need for liquidity is to fund working capital requirements, capital expenditures, and for general corporate purposes. The Company's ability to fund operations and make planned capital expenditures and debt service obligations depends on future operating performance and cash flows, which are subject to prevailing economic conditions, financial markets, business and other factors. We have recorded a net loss of \$1,823,618 and \$3,915,207 for the three and nine months ended September 30, 2021, respectively, and \$973,327 and \$2,587,062 for the three and nine months ended September 30, 2020, respectively. We have recorded an accumulated deficit of \$17,173,083 as of September 30, 2021 and \$12,521,944 as of December 31, 2020. Net cash used in operating activities for the nine months ended September 30, 2021 and September 30, 2020 was \$3,017,468 and \$1,633,774, respectively.

We believe that our available cash and the net proceeds from the initial public offering will be sufficient to satisfy our liquidity requirements for at least the next twelve months from the date of the issuance of the financial statements. Our liquidity assumptions may prove to be incorrect, and we could utilize our available financial resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:

- the cost and timing of our regulatory activities, especially the process to obtain regulatory approval for our intellectual properties in the U.S. and in foreign countries
- the costs of R&D activities we undertake to further develop our technology
- the costs of constructing our grow houses, including any impact of complications, delays, and other unknown events
- the costs of commercialization activities, including sales, marketing and production
- · the level of working capital required to support our growth
- · our need for additional personnel, information technology or other operating infrastructure to support our growth and operations as a public company

We may need to raise additional capital to execute our business plan. If we are unable to raise additional capital when desired, or on terms acceptable to us, our business, results of operations, and financial condition would be adversely affected.

#### **Cash Flows**

The net cash used by operating activities for the nine months ended September 30, 2021 is attributable to a net loss of \$3,915,207 due to operating costs associated with wages, investor relations, consulting expenses, professional fees, research and development, and general administrative expenses. The net loss was adjusted primarily by non-cash expenses related to shared based compensation of \$571,398 and shares issued for consulting services amounting to \$298,214. For the nine months ending September 30, 2020 net cash used by operating activities was attributable to net loss of \$2,587,062 owing to wages, consulting expenses, professional fees, research and development expenses and general administrative expenses. The net loss was adjusted primarily by non-cash expenses of shared based compensation of \$463,882 and shares issued for consulting services amounting to \$418,926.

The net cash used in investing activities for nine months ended September 30, 2021 and 2020 represents capitalized furniture, computer and office equipment costs.

Cash provided by financing activities for the nine months ended September 30, 2021 mainly represents proceed from the IPO net of underwriting discount and issue costs of \$13,360,616, proceeds from issuance of senior secured debentures, net of transaction costs, of \$531,000, as well as proceeds from long-term loan of \$15,932, which was offset by repayment of senior secured debentures of \$750,000. Cash provided by financing activities for the nine months ended September 30, 2020 represents proceeds from long-term loan of \$29,987, which was offset by payments of IPO costs amounting to \$41,200.

#### **Recent Financings**

On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of \$750,000 in principal amount (\$600,000 subscription amount) of senior secured debentures originally due June 24, 2021. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended. On June 24, 2021, the due date was extended, and the senior secured debentures were repaid in full on July 13, 2021.

On July 12, 2021, the Company completed its IPO whereby it sold a total of 3,127,998 units, each consisting of one common share and one Series A warrant to purchase one common share, at a public offering price of \$5.00 for gross proceeds of \$15,639,990. The Company received net proceeds from the IPO of \$14,388,791, after deducting underwriting discounts and commissions of 1,251,199.

#### **Off Balance Sheet Arrangements**

None.

#### **Significant Accounting Policies**

See the footnotes to our unaudited financial statements for the nine months ended September 30, 2021 and 2020, included with this quarterly report.

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item.

#### Item 4. Controls and Procedures

#### Disclosure Controls and Procedures.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our management is also required to assess and report on the effectiveness of our internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 ("Section 404"). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States. Management assessed the effectiveness of our internal control over financial reporting as of September 30, 2021. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework in the 2013 COSO framework. Based on this assessment, management concluded that our disclosure controls and procedures were effective.

#### Changes in Internal Controls.

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

#### Limitations on Effectiveness of Controls and Procedures

Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving the desired control objectives. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

#### PART II — OTHER INFORMATION

#### Item 1. Legal Proceedings

For a discussion of legal proceedings, see Note 10 to the unaudited condensed consolidated financial statements included under Part I, Item 1 of this report.

#### Item 1A. Risk Factors

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of \$750,000 in principal amount (\$600,000 subscription amount) of senior secured debentures due June 24, 2021. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended.

During the three months ended March 31, 2021, the Company issued 30,000 restricted common shares to a third-party consultant. The common shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

On May 10, 2021, the Company declared and, on May 11, 2021 issued, 86,739 restricted common shares as stock dividend to holders of Series a Preferred shares issued on May 2, 2019. The securities were issued pursuant to the exemption from the prospectus requirements of applicable Canadian provincial securities laws provided by Section 2.42(1) of NI 45-106 on the basis that the issuance is a distribution in accordance with the terms of a previously issued security.

On May 10, 2021, the Company declared, and on May 11, 2021 issued, 48,791 restricted common shares as stock dividend to holders of Series A Preferred shares issued on May 10, 2019. The securities were issued pursuant to the exemption from the prospectus requirements of applicable Canadian provincial securities laws provided by Section 2.42(1) of NI 45-106 on the basis that the issuance is a distribution in accordance with the terms of a previously issued security.

On May 27, 2021, the Company issued to consultants a total of 7,237 restricted common shares. The securities were issued pursuant to the exemption from the prospectus requirements of applicable Canadian provincial securities laws provided by Section 2.24(1) of NI 45-106 on the basis that the issuance is a distribution to consultants of the Company.

On May 27, 2021, the Company issued 820,029 restricted common shares as a result of 1,113,701 stock options exercised on a cashless basis at various exercise price. The securities were issued pursuant to the exemption from the prospectus requirements of applicable Canadian provincial securities laws provided by Section 2.24(1) of NI 45-106 on the basis that the issuance is a distribution to employees, officers, and consultants of the Company.

On May 28, 2021, the Company's officers opted to receive a total of 98,356 restricted common shares as bonus compensation for services rendered and accrued for in 2019 and 2020. The securities were issued pursuant to the exemption from the prospectus requirements of applicable Canadian provincial securities laws provided by Section 2.24(1) of NI 45-106 on the basis that the issuance is a distribution officers of the Company.

On June 24, 2021, the Company issued to a consultant working with the senior secured debentures holders, a total of 10,000 restricted common shares on their behalf. The common shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

On July 28, 2021, 93,938 common stock purchase warrants were issued to the purchaser of the senior secured debentures, with a term of three years and a strike price per share of \$3.99.

On July 12, 2021, the company issued to a vendor a total of 15,000 restricted common shares. The common shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended

On July 15, 2021, the company issued 39,800 common shares on exercise of Series A Purchase Warrants.

On September 1, 2021, the company issued 19,992 restricted shares to its directors as settlement of accrued directors' fee. The common shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

On July 12, 2021, the Company declared and issued, 53,475 restricted common shares as final stock dividend to holders of Series A Preferred shares issued on May 02, 2019 and May 10, 2019. The securities were issued pursuant to the exemption from the prospectus requirements of applicable Canadian provincial securities laws provided by Section 2.42(1) of NI 45-106 on the basis that the issuance is a distribution in accordance with the terms of a previously issued security.

#### Item 3. Defaults Upon Senior Securities

None.

#### Item 4. Mine Safety Disclosures

Not applicable.

#### Item 5. Other Information

None.

#### Item 6. Exhibits

- 31.1 <u>Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*</u>
- 31.2 <u>Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*</u>
- 32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*
- 32.2 <u>Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*</u>
- 101.ins Inline XBRL Instance Document\*\*

 101.sch
 Inline XBRL Taxonomy Schema Document\*\*

 101.cal
 Inline XBRL Taxonomy Calculation Document\*\*

 101.def
 Inline XBRL Taxonomy Linkbase Document\*\*

 101.lab
 Inline XBRL Taxonomy Label Linkbase Document\*\*

 101.pre
 Inline XBRL Taxonomy Presentation Linkbase Document\*\*

 104
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

<sup>\*</sup> Furnished herewith

<sup>\*\*</sup> Filed herein

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

#### AGRIFORCE GROWING SYSTEMS, LTD.

Date: November 15, 2021 By: /s/Ingo Mueller

Name: Ingo Mueller

Title: Chief Executive Officer and Director (Principal Executive Officer)

Date: November 15, 2021 By: /s/ Richard Wong

Name: Richard Wong

Title: Chief Financial Officer (Principal Financial and Accounting Officer)

19

### CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

#### I, Ingo Mueller, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of AgriForce Growing Systems, Ltd.
- 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report.
- 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report.
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;
  - designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
  - a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) any fraud, whether material, which involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Dated: November 15, 2021

By: /s/Ingo Mueller

Ingo Mueller

Chief Executive Officer (Principal Executive Officer)

## CERTIFICATION OF PRINCIPAL EXECUTIVE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

#### I, Richard Wong, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of AgriForce Growing Systems, Ltd.
- 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which
    this quarterly report is being prepared;
  - designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
  - a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) any fraud, whether material, which involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Dated: November 15, 2021 By: /s/Richard Wong

Richard Wong

Chief Financial Officer (Principal Financial and Accounting Officer)

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

About the Quarterly Report of AgriForce Growing Systems, Ltd. (the "Company") on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Ingo Mueller, Chief Executive Officer (Principal Executive Officer) of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 15, 2021

By: /s/ Ingo Mueller

Ingo Mueller

Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AgriForce Growing Systems, Ltd. (the "Company") on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Richard Wong, Chief Financial Officer, Secretary and Director (Principal Financial and Accounting Officer) of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 15, 2021

By: /s/ Richard Wong

Richard Wong

Chief Financial Officer (Principal Financial and Accounting Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.